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Paraoxonase activity in metabolic syndrome in children 
and adolescents 
   
Abstract 
Background: Metabolic syndrome (MetS) is a collection of various interrelated risk 
factors that appear to have an impact as development of atherosclerotic cardiovascular 
disease (CVDs). Epidemic of childhood and adolescent’s obesity has increased interest in 
the metabolic syndrome (MS) due to the potential projection into adulthood. The 
prevalence of MS in adolescents has been estimated to be 6.7% in young adults and 4.2% 
in adolescents. We aimed to study the MetS in children and adolescents with respect to 
metabolic changes. 
Methods: The international Diabetes Federation criteria were used for the selection of 
cases. Serum paraoxonase 1 (PON1) activities were measured using spectrophotometer. 
Statistical analysis was done using MyStat statistical software. 
Results: Serum PON1 arylesterase (ARE) and lactonase (LACT) activities were found to 
be reduced significantly in patients with MetS than in controls. Regression analysis 
showed a significant correlation between PON1 activities and body mass index. Area 
under curve (AUC) found to increase from HDL to PON1 ARE to PON1 LACT. 
Conclusions: From the present study, it is clear that in children and adolescents, reduction 
in PON1 activities in MetS is mainly due either to abnormalities with synthesis or 
secretion of HDL cholesterol or oxidative stress as a consequence of excess production of 
the free radicals. This study also iterates that it is the quality and not the quantity of HDL 
cholesterol which is important while studying the pathophysiology of MetS. 
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The lifestyle changes are leading to dreadful metabolic disorders. The metabolic 
syndrome is one of them. The metabolic syndrome (MetS) is a collection of various 
interrelated risk factors that appear to have impact as the development of atherosclerotic 
cardiovascular disease (CVDs) (1). It is linked with marked increase in cardiovascular risk 
associated with clustering of risk factors. The central features of the metabolic syndrome 
are insulin resistance, visceral adiposity, atherogenic dyslipidemia and endothelial 
dysfunction (2, 3).  
 
It is more disastrous in children and adolescents. Epidemic of childhood and 
adolescent obesity has increased the interest in the metabolic syndrome (MS) due to the 
potential projection into adulthood. The prevalence of the MS in adolescents has been 
estimated to be 6.7% in young adults and 4.2% in adolescents. The definitions of 
metabolic syndrome include those proposed by the World Health Organization (WHO), 
the European Group for the Study of Insulin Resistance (EGIR), the US National 
Cholesterol Education Program (ATPIII) and International Diabetes Federation (IDF) (4-
7).
 
Along with obesity, various other factors increase susceptibility for MetS (8). All 
individual components of MetS are risk factors for CVD. 
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PATHOPHYSIOLOGY OF METABOLIC SYNDROME 
Insulin resistance and Obesity: Insulin resistance (IR) and 
obesity seem to be important risk factors for MetS. IR is 
contributed by free fatty acids (FFAs) which reduce insulin 
sensitivity in muscle by inhibiting insulin-mediated glucose 
uptake. In the liver, FFAs increase the production of glucose, 
triglycerides (TG) and very low density lipoproteins 
(VLDL). Consequently, there is reduced glycogen formation, 
increased lipid accumulation in TG, lipolysis and increased 
inflammatory cytokines (9-12). Obesity is associated with 
the development of oxidative stress & IR (13-15). 
PARAOXONASE: Paraoxonase (PON) is a family of Ca
++
 
dependent enzymes namely PON1, PON2 and PON3 the 
gene which is located on chromosome 7q21.3-22.1 (16, 17).
 
Paraoxonase1 (PON1) is exclusively associated with HDLc 
and is a genetically polymorphic enzyme. It plays a vital role 
in the prevention of microvascular complications due to 
oxidative stress and against various toxic chemicals (18). 
The HDL oxidation is stopped by PON1-mediated 
hydrolysis of lipid peroxides (19). Thus, the aim of the 
present study was to estimate PON1 arylesterase (ARE), 
lactonase (LACT) activity in patients with metabolic 
syndrome and to compare PON1 activities in children and 
adolescents with metabolic syndrome and the controls. 
 
 
Methods 
The study was approved by the Institutional Ethics 
Committee and conducted during December 2014 to May 
2015 in tertiary care hospital affiliated to a rural medical 
college in Maharashtra, India. A total of 124 subjects were 
enrolled in the study. Sample size was calculated using 2-
sided 95% confidence interval and 80% power. Using the 
mean and SD form of our pilot study, the necessary sample 
size came to be 56. Therefore a total of 62 subjects were 
enrolled as cases and controls. Cases were selected randomly 
to avoid the selection bias from the patients visiting the 
hospital. For randomization, random number generator 
software was used. Cases were included as per criteria put 
forth by IDF (7). Subjects were eligible if they were healthy, 
age between 4 and 20 years, with a body-mass index (BMI, 
the weight in kilograms divided by the square of the height 
in meters) that exceeded the 97th percentile for their age and 
sex. Exclusion criteria were the known presence of diabetes 
and the use of medication that alters blood pressure or 
glucose or lipid metabolism. As per the Helsinki declaration, 
written informed consent was taken from parents or legal 
guardians of all the participants. With all aseptic precautions 
early morning fasting blood samples were collected by 
venipuncture from the cases.  
From the control subjects, blood samples were collected 
at the time of their routine clinical visits through 
venipuncture. Samples were analyzed immediately after 
processing. Serum PON1 ARE activity was measured 
spectrophotometrically at 270 nm with 3 mL buffer-substrate 
solution containing 20 mmol Tris-hydroxymethyl (HCI) 
buffer and 4 mmol phenylacetate as substrate at pH 8.0 and 5 
μl serum. Serum PON1 LACT was measured 
spectrophotometrically at 270 nm with 2 mL buffer substrate 
solution containing 50 mmol Tris-HCl buffer and 1 mmol 
dihydroxycoumarin as substrate at pH 8.0 and 10 μl serum 
(20, 21). Normality of the distribution of the arylesterase and 
lactonase activity was assessed by Shapiro-Wilk test. Two 
sample t-test was applied for hypothesis testing. Results 
were expressed as mean±SD for all continuous variables. 
The statistical significance level was set at 0.05. There were 
no differences between the two groups with regard to age 
and sex. The results obtained were analyzed using Mystat 
statistical software. 
 
 
Results 
 Serum PON1 arylesterase activity reduced significantly 
in cases of MetS than in controls. Similarly, serum PON1 
lactonase activity reduced significantly in cases of MetS. 
The results show that arylesterase and lactonase singly can 
correlate well with BMI and their combination even more so. 
The study parameters are shown in table 1. 
Table 1: The study parameters 
Parameter 
Cases 
(n=62) 
(mean±SD) 
Controls 
(n=62) 
(mean±SD) 
P-
value 
Age (Yrs) 16.8±2.12 17.3±1.84 0.245 
BMI (Kg/m
2
) 31.52±3.2 19.1±3.53 <0.001 
HDL Cholesterol 
(mg/dl) 
32.17±3.24 34.37±4.16 0.0025 
PON1 Arylesterase 
(kU/L) 
97.36±23.09 115.63±24.43 0.0003 
PON1 Lactonase 
(U/L) 
5.58±1.34 6.69±1.63 0.0005 
BMI: Body mass index, PON: Paraoxonase, SD: Standard 
deviation, HDL: High-density lipoprotein 
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The receiver operator characteristic (ROC) curve shows 
an increase in area under curve (AUC) as we go from HDL 
to PON1 ARE to PON1 LACT. Cox & Snell R
2 
as well as 
Naglekerke’s R2 also increased in the similar manner. It is 
shown in figure 1 (A, B, C). From the ROC curve, it is clear 
that PON1 activities are better predictors of metabolic 
syndrome in children and adolescents than lipid profile or 
HDL levels. Logistic regression analysis shows area under 
curve (AUC) as 0.623, 0.851 and 0.953 for HDL, PON1 
ARE and PON1 LACT, respectively. Cox & Snell R
2 
comes 
out to be 0.056, 0.336 and 0.553 respectively for HDL, 
PON1 ARE and PON1 LACT. Nagelkerke’s R2 is 0.075, 
0.448 and 0.954 for HDL, PON1 ARE and PON1 LACT 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Receiver operator characteristic (ROC) curve for HDL, ARE & LACT 
AUC: area under curve, HDL: high density lipoprotein, PON1: paraoxonase 1, ARE: arylesterase, LACT: lactonase 
 
Linear regression analysis shows R=-0.495 indicating 
significant correlation between arylesterase and BMI 
(p<0.001). Similarly, serum lactonase activity of PON1 also 
reduced in BMI. Its linear regression analysis showed R=-
0.646 suggesting significant correlation between lactonase 
and birth weight (p<0.001). Both these show the significant 
negative correlation with BMI. 
 
 
Discussion 
To the best of our knowledge, this is the first study 
considering the correlation of metabolic syndrome with 
serum arylesterase and lactonase activities in combination in 
children and adolescent population. Plasma PON1 activity 
was found to be altered, usually decreased in number of 
pathological conditions and diseases (22).
 
In the present 
study, we found that there is a significant reduction in the 
PON1 arylesterase and lactonase activity in children and 
adolescents with metabolic syndrome. 
It appears that the arylesterase and lactonase activities of 
PON1 are new and independent markers for MetS. Some of 
the researchers found the significant negative correlation  
 
between oxidative stress and PON1 levels (23). It can be  
hypothesized that the oxidative damage to the lipoproteins  
especially HDL leads to reduced PON1 activity. 
Biochemical findings of metabolic syndrome show the 
reduced HDL cholesterol. Decreased concentration of HDLc 
is correlated with reduced PON1 activities (24). Our results 
depict though not very significant the positive correlation of 
HDLc with arylesterase and lactonase. 
The reduced PON1 activities are supposed to be the 
consequence of dysfunctional or modified HDLc which is 
responsible for the reduced antioxidant capacity (25).
 
As 
PON1 prevents oxidation of LDL and HDL, qualitative 
changes in lipoproteins coupled with reduced HDLc 
concentration leading to reduced PON1 activity, render them 
more susceptible to oxidative damage. Progressive decline in 
enzymatic capacity of PON1 with disease severity of MetS 
inactivates PON1 (26) as a likely consequence of oxidative 
stress in the metabolic syndrome, exceeding the antioxidant 
capacity of the enzyme can be the possible explanation of 
reduced PON1 activity. Literature states severity of MetS is 
directly proportional to oxidative stress which inactivates 
PON1 function (26). But at the same time, the possibility 
that low PON1 function fails to provide an efficient 
protection against MetS relates oxidative damage that cannot 
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be excluded. PON1 is capable of protecting lipoproteins 
against the effect lipid peroxidation by degrading specific 
oxidized cholesteryl esters and phospholipids, and 
antioxidant properties of HDL have been attributed, at least 
partially to PON1 (27). This may be the possible explanation 
for reduced PON1 activity found in MetS. Some researchers 
revealed that a low PON1 concentration is typical in MetS 
and may significantly lower HDLc concentration. It has also 
been proposed that these results be taken into account not 
only the HDL quantity but also HDL quality, which could be 
reflected, at least in part by PON1 concentration or activity 
(28). This is because PON1 is HDL-associated enzyme. This 
supports the findings that PON1 correlates well with MetS. 
The reductions in the activities of PON1 found in the 
present study and their relationship to HDL-cholesterol 
suggest that the decrease of these serum enzymes may 
participate in the pathogenesis of metabolic syndrome. The 
altered PON1 arylesterase and lactonase activities in 
metabolic syndrome could have two possible explanations. 
One is that serum PON1 activities may be lowered as a result 
of an altered synthesis or secretion of HDL-cholesterol. The 
other one is the overproduction of the free radicals. Free 
radicals are disproportionately formed in metabolic 
abnormalities by oxidation and subsequent oxidative 
degradation of proteins. Insulin resistance seems to stimulate 
endothelial superoxide anion production via nicotinamide 
adenine dinucleotide phosphate hydrolase (29) and hence can 
worsen the degree of oxidative stress. Taken together, these 
observations strongly suggest that the activation of 
oxidative-stress pathways is a key component of the 
metabolic syndrome. In family history of metabolic 
syndrome, obesity is not taken into consideration in the 
present study which may be a possible limitation of the 
study. But the probability of affecting the result of the 
present study is very small. 
In conclusion from the present study, it is clear that the 
reduction in PON1 activities in MetS mainly due either to 
abnormalities with synthesis or secretion of HDLc or 
oxidative stress which is a consequence of excess production 
of the free radicals. This study also iterates that it is the 
‘quality’ and not the quantity of HDLc which needs to be 
taken into account while studying the pathophysiology of 
MetS and PON1 effectively put forth the ‘quality ’ of HDLc. 
Therefore our study recommends PON1 as a tool to assess 
the severity of MetS. 
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